The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models

Gene Therapy

Volumn 18, Issue 12, 2011, Pages 1157-1165

  Cherubini, G ^a   Kallin, C ^b   Mozetic, A ^a   Hammaren Busch, K ^b   Muller H ^a   Lemoine, N R ^a   Hallden G ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

adenocarcinoma; gemcitabine; in vivo; irinotecan; sensitization

Indexed keywords

CISPLATIN; GEMCITABINE; IRINOTECAN; ONCOLYTIC ADENOVIRUS;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRONCHUS MUCOSA; CANCER CELL CULTURE; CELL CYCLE; CELL GROWTH; CELL KILLING; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; DRUG EFFICACY; DRUG SELECTIVITY; GENE DELETION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR GROWTH; VIRUS REPLICATION;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; GENETIC VECTORS; MICE; MICE, INBRED C57BL; MICE, NUDE; ONCOLYTIC VIRUSES; PANCREATIC NEOPLASMS; VIRUS REPLICATION; VIRUS SHEDDING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ONYX;

EID: 83255185076     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.141     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277. (Pubitemid 46143304)
3. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5: 965-976. (Pubitemid 41766784)
4. Aghi M, Martuza RL. Oncolytic viral therapies-the clinical experience. Oncogene 2005; 24: 7802-7816. (Pubitemid 41670681)
5. Dorer DE, Nettelbeck DM. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev 2009; 61: 554-571.
6. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007; 4: 101-117. (Pubitemid 46189539)
7. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 2006; 14: 107-117. (Pubitemid 43899483)
8. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376. (Pubitemid 26353341)
9. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006; 98: 298-300.
10. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6: 611-623. (Pubitemid 40017704)
11. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Therapy 2001; 8: 89-98. (Pubitemid 32162422)
12. Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson III A, Galanis E et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 1498-1504. (Pubitemid 46594102)
13. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885. (Pubitemid 30644745)
14. Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Therapy 2005; 12: 437-445. (Pubitemid 40394296)
15. Kumar S, Gao L, Yeagy B, Reid T. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 2008; 10: 371-379.
16. Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003; 9: 555-561. (Pubitemid 36182584)
17. Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C et al. Safety and feasibility of injection with an E1B-55kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Therapy 2001; 8: 308-315. (Pubitemid 32237064)
18. O'Shea CC, Choi S, McCormick F, Stokoe D. Adenovirus overrides cellular checkpoints for protein translation. Cell Cycle 2005; 4: 883-888. (Pubitemid 41359751)
19. Wang Y, Hallden G, Hill R, Anand A, Liu TC, Francis J et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 2003; 21: 1328-1335. (Pubitemid 37356618)
20. Fulci G, Dmitrieva N, Gianni D, Fontana EJ, Pan X, Lu Y et al. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res 2007; 67: 9398-9406. (Pubitemid 47535930)
21. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000; 6: 1134-1139.
22. Page JG, Tian B, Schweikart K, Tomaszewski J, Harris R, Broadt T et al. Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. Am J Obstet Gynecol 2007; 196: 389. e381-389; discussion 389 e389-310.
23. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12. (Pubitemid 30066345)
24. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR et al. Genetic profile of pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 2001; 439: 798-802. (Pubitemid 33141325)
25. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57: 3126-3130. (Pubitemid 27351723)
26. Raki M, Sarkioja M, Desmond RA, Chen DT, Butzow R, Hemminki A et al. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol Oncol 2008; 108: 166-172. (Pubitemid 350299441)
27. Lockley M, Fernandez M, Wang Y, Li NF, Conroy S, Lemoine N et al. Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin. Cancer Res 2006; 66: 989-998. (Pubitemid 43165967)
28. Liu TC, Hallden G, Wang Y, Brooks G, Francis J, Lemoine N et al. An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency. Mol Ther 2004; 9: 786-803. (Pubitemid 38878125)
29. Liu TC, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR et al. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus. Gene Therapy 2005; 12: 1333-1346. (Pubitemid 43084489)
30. Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, Lemoine NR et al. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res 2009; 15: 1730-1740.
31. Oberg D, Yanover E, Sweeney K, AdamV, Costas C, Lemoine NR et al. Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant (AdDD) in prostate and pancreatic cancers. Clin Canc Res 2010; 16: 541-553.
32. Lipton A, Campbell-Baird C, Witters L, Harvey H, Ali S. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. J Clin Gastroentero 2010; 44: 286-288.
33. Sun W, Metz JM, Gallagher M, O¢Dwyer PJ, Giantonio B, Whittington R et al. Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas. Cancer Chemother Pharmacol 2011; 67: 621-627.
34. Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemciabine-refractory advanced pancreatic cancer. Br J Cancer 2009; 101: 1658-1663.
35. Sundararajan R, Cuconati A, Nelson D, White E. Tumor necrosis factor-alpha induces Bax-Bak interaction and apoptosis, which is inhibited by adenovirus E1B 19K. J Biol Chem 2001; 276: 45120-45127.
36. Sundararajan R, White E. E1B 19K blocks Bax oligomerization and tumor necrosis factor alpha-mediated apoptosis. J Virol 2001; 75: 7506-7516. (Pubitemid 32738009)
37. Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD et al. Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. Hum Gene Therapy 2008; 19: 873-886.
38. Radhakrishnan S, Miranda E, Ekblad M, Holford A, Pizarro MT, Lemoine NR et al. Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts. Hum Gene Ther 2010; 21: 1311-1325.
39. Raki M, Kanerva A, Ristimaki A, Desmond RA, Chen DT, Ranki T et al. Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Therapy 2005; 12: 1198-1205. (Pubitemid 41136314)
40. Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF et al. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res 2006; 12: 556-562. (Pubitemid 43166149)
41. Hamacher R, Schmid RM, Saur D, Schneider G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer 2008; 7: 64.
42. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001; 61: 517-525. (Pubitemid 32128610)
43. Conrad C, Miller CR, Ji Y, Gomez-Manzano C, Bharara S, McMurray JS et al. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther 2005; 12: 284-294. (Pubitemid 40315188)
44. Cantore M, Rabbi C, Fiorentini G, Oliani C, Zamagni D, Iacono C et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 2004; 67: 93-97. (Pubitemid 39482675)
45. Cherubini G, Petouchoff T, Grossi M, Piersanti S, Cundari E, Saggio I. E1B55K-deleted adenovirus (ONYX-015) overrides G1/S and G2/M checkpoints and causes mitotic catastrophe and endoreduplication in p53-proficient normal cells. Cell Cycle 2006; 5: 2244-2252. (Pubitemid 44546561)
46. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, Kern SE. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994; 54: 3025-3033. (Pubitemid 24187791)